ArticleJournal of Maine Medical Center2026
Survey of MaineHealth Cancer Care Network Providers on Cannabis Use: Preparation for Studies Sponsored by the National Cancer Institute.
Article in Journal of Maine Medical Center, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Cannabis and cannabinoid use in patients with cancer has rapidly scaled up over the past decade and is a topic of considerable clinical, research, and public health interest. Methods: We conducted a cannabis landscape survey among front-line providers in the MaineHealth Cancer Care Network (MHCCN) before applying and participating in National Cancer Institute (NCI)-sponsored studies on cannabis use in patients with cancer. The results of the survey can better inform participation in national studies and provide a departure point for provider educational activities focused on cannabis use in the cancer care setting. Results: Notable observations from our survey included a 58% (100/171) response rate, which signals awareness and interest in cannabis use by our provider teams. Also, 30% of providers/care team members inquire about their patients' cannabis use, 89% agree that cannabis can be effective for managing symptoms, 54% are sensitive to stigma surrounding cannabis use (as well as 57% of their patients), only 15% considered themselves knowledgeable, and 85% are receptive to learning more about cannabis use. Discussion: These observations confirmed interest among our care teams to engage in cannabis-focused studies. They also paved a way toward participating in NCI-sponsored studies to address gaps in knowledge and the benefits and harms of cannabis and cannabinoid use in patients with cancer. Barriers and themes from the survey related to conducting research in this therapeutic area are discussed. Conclusions: Longitudinal studies evaluating the benefits and harms of cannabis use remain scarce. Significant gaps in knowledge persist for both providers and patients, compounded by regulatory, ethical, and drug provision hurdles in this research area. Our survey results offer a foundation for educating care team members about cannabis use. Alongside participation in a large, first-ever national study, we outline plans for a small pilot study that uses an innovative application to capture cannabis use and product type.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.